Researchers at McMaster University are heralding the success of early trials of a “booster” vaccine that could serve as a potent tool in global fight against tuberculosis.
In a report published on Wednesday in the journal Science Translational Medicine, researchers with the university’s Michael G. DeGroote School of Medicine detail a study they conducted with 24 human volunteers to test the safety of the vaccine.
Zhou Xing, a professor of pathology and molecular medicine at the McMaster Immunology Research Centre, said the test subjects developed no major side effects. Generally, their immune systems responded well to the vaccine.
“We are excited,” Xing said. “We are encouraged by these promising results.”
Read the full, original story here: “Genetically modified cold virus a ‘promising’ new TB vaccine”
